comparative valuations.

For those trying to value up AVH , perhaps three companies to look at are TIS. $90M. RVA. $230M, GID. $230 Million.

All three of those companies are ASX listed and on the path to commercialization, GID and RVA have more cash on hand than AVH but have trials to pay for.

AVH trials are funded by DoD, so in effect a similar situation.

TIS GID AVH are selling in Europe but not yet approved in US.


TIS hS the cheapest product appealing to a wide audience.

Then AVH product is next with GID and RVA the dearest.

AVH and TIS compete in some areas and not others.

AVH has no competition for several uses, GID has no competitors.

RVA has leading edge technology but several others competing for the space.

Weighing up all the factors $50 MC for AVH ,is the lowest valuation by far. With three other companies between 2 and 5 times AVH valuation, investors could feel relatively certain they are buying in at the lower end of valuations.

.